Colon Cancer

Anti-inflammatory drug fails to prevent a hereditary form of disease

Published in Cancer Weekly, April 30th, 2002

The anti-inflammatory drug sulindac may not have the colon cancer prevention properties once hoped for, say Johns Hopkins Kimmel Cancer Center researchers.

Results of a 4-year study, described in the April 4, 2002, issue of the New England Journal of Medicine, show that sulindac did not prevent precancerous growths, called polyps, in young patients with a hereditary form of colon cancer. The drug may still have benefit in reducing polyps in older patients.

Researchers followed 41 patients ages 8-25 with known genetic mutations that result in a form of hereditary colon cancer, called familial adenomatous polyposis (FAP) or Gardner syndrome,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2002-04-30)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry